Dipeptidyl peptidase 4 (DPP4) inhibition inhibits the N-terminal deactivation of GIP and GLP1, thereby enhancing the natural incretin activity, which is an effective treatment for patients with T2D [112]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.